11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Botulinum neurotoxins (BoNTs) form a growing family of metalloproteases with a unique specificity either for VAMP, SNAP25 or syntaxin. The BoNTs are grouped in seven different serotypes indicated by letters from A to G. These neurotoxins enter the cytosol of nerve terminals via a 100 kDa chain which binds to the presynaptic membrane and assists the translocation of a 50 kDa metalloprotease chain. These two chains are linked by a single disulfide bridge which plays an essential role during the entry of the metalloprotease chain in the cytosol, but thereafter it has to be reduced to free the proteolytic activity. Its reduction is mediated by thioredoxin which is continuously regenerated by its reductase. Here we show that inhibitors of thioredoxin reductase or of thioredoxin prevent the specific proteolysis of VAMP by the four VAMP-specific BoNTs: type B, D, F and G. These compounds are effective not only in primary cultures of neurons, but also in preventing the in vivo mouse limb neuroparalysis. In addition, one of these inhibitors, Ebselen, largely protects mice from the death caused by a systemic injection. Together with recent results obtained with BoNTs specific for SNAP25 and syntaxin, the present data demonstrate the essential role of the thioredoxin-thioredoxin reductase system in reducing the interchain disulfide during the nerve intoxication mechanism of all serotypes. Therefore its inhibitors should be considered for a possible use to prevent botulism and for treating infant botulism.

          Related collections

          Author and article information

          Journal
          Biochem. Pharmacol.
          Biochemical pharmacology
          Elsevier BV
          1873-2968
          0006-2952
          Dec 01 2015
          : 98
          : 3
          Affiliations
          [1 ] Dipartimento di Scienze Biomediche, Università di Padova, Via U. Bassi 58/B, 35121 Padova, Italy.
          [2 ] Institut für Biochemie, OE 4310, Medizinische Hochschule Hannover, 30623 Hannover, Germany.
          [3 ] Public Health England, Porton Down, Salisbury, Wiltshire SP4 OJG, UK.
          [4 ] Histology and Molecular Biology Section, Army Medical and Veterinary Research Center, Via Santo Stefano Rotondo 4, 00184 Rome, Italy.
          [5 ] Dipartimento di Scienze Biomediche, Università di Padova, Via U. Bassi 58/B, 35121 Padova, Italy; Istituto CNR di Neuroscienze, Università di Padova, Via U. Bassi 58/B, 35121 Padova, Italy. Electronic address: cesare.montecucco@gmail.com.
          Article
          S0006-2952(15)00654-1
          10.1016/j.bcp.2015.09.023
          26449594
          d4e4b298-6a7e-4751-9548-1c425736be98
          History

          Botulism,Peripheral neuroparalysis,PX12 (PubChem CID: 219104),Myricetin (PubChem CID: 5281672),Inhibitors,Ebselen (PubChem CID: 3194),Ebselen,Curcumin (PubChem CID: 969516),Botulinum neurotoxins,Thioredoxin system

          Comments

          Comment on this article